Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Implantable cardioverter-defibrillators (ICDs) are used for sudden cardiac death (SCD) prophylaxis in high-risk patients.
• While some trials show ICD benefits, others do not demonstrate survival advantages.
• Identifying specific patient subgroups who benefit most from ICDs is essential.

Purpose of the Study:

• To review the evidence for implantable cardioverter-defibrillator (ICD) use in preventing sudden cardiac death.
• To evaluate the effectiveness of ICDs in various patient populations, including those with ischemic and non-ischemic cardiomyopathy.
• To consider the role of cardiac resynchronization therapy (CRT) and the economic implications of ICDs.

Main Methods:

• Systematic review of key clinical trials, including MADIT II and SCD-HeFT.
• Analysis of patient populations defined by cardiomyopathy type, heart failure severity, and inherited arrhythmia conditions.
• Consideration of comparative effectiveness against antiarrhythmic drugs and optimal medical therapy.

Main Results:

• ICDs demonstrated reduced mortality in patients with ischemic cardiomyopathy (MADIT II).
• ICDs prevented sudden cardiac death and all-cause mortality in high-risk heart failure patients (SCD-HeFT).
• Cardiac resynchronization therapy (CRT) improves outcomes in advanced heart failure.

Conclusions:

• ICDs are effective in selected high-risk populations for preventing sudden cardiac death.
• Patient selection is critical to maximize survival benefits and justify the economic cost of ICDs.
• Further research may refine criteria for optimal ICD implantation in diverse cardiac conditions.